This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Verzenio
  • /
  • A Study of Abemaciclib (LY2835219) in Participants...
Clinical trial

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)

Read time: 2 mins
Last updated:1st Oct 2014
Identifier: NCT02152631

The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Estimated Enrollment: 450
Study Start Date: October 2014
Estimated Study Completion Date: November 2018
Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Abemaciclib
- Active Comparator: Erlotinib

Category Value
Date last updated at source 2017-10-19
Study type(s) Interventional
Expected enrolment 450
Study start date 2014-10-01
Estimated primary completion date 2017-09-01

View full details